TikTok's Gray Market for GLP-1 Drugs Raises Safety Concerns Amid Ongoing Moderation Issues

A growing concern has emerged surrounding TikTok and its handling of an unregulated, gray market for GLP-1 weight-loss drugs, as highlighted in a new report by the gender justice nonprofit UltraViolet. The investigation reveals numerous TikTok accounts that promote GLP-1 alternatives, some marketed as "research-grade," which are not sanctioned for public use by health regulatory authorities.

The analysis documented hundreds of accounts that encourage users to purchase GLP-1 drugs through external platforms like WhatsApp, Discord, and Telegram, circumventing TikTok's own marketplace. Notably, content about these pharmaceuticals, including the non-FDA approved retatrutide, remained readily accessible across both TikTok accounts and non-users. Even after a change in platform ownership in early 2026, these drugs were noticeably featured, raising alarms about TikTok's content moderation practices.

Targeted Messaging Amplifies Concerns

UltraViolet's findings reveal a disturbing trend in which posts often target women, utilizing images of both real and AI-generated women. Many of these posts promote harmful narratives concerning weight loss and body image, sometimes containing misleading claims about women's health and wellness. This calculated approach underscores the platform's potential role in perpetuating unhealthy behaviors, especially among vulnerable demographics.

The nonprofit submitted reports about 202 specific accounts to TikTok for violating its Community Guidelines. While approximately one-third of these accounts were eventually removed, the low removal rate signals potential gaps in TikTok’s content moderation system. In its report, UltraViolet indicated that the rampant and easily accessible nature of this content points to a widespread problem likely to remain unaddressed unless more robust actions are taken.

Policy and Regulatory Gaps

While TikTok has updated its Community Guidelines following its ownership transition, the platform still does not outright prohibit discussions around GLP-1 products. Instead, TikTok allows pharmaceutical advertising that adheres to regional laws, albeit with restrictions against promoting disordered eating or dangerous weight loss practices.

Specifically, TikTok’s advertising guidelines disallow any materials that promote unsafe mental health behaviors or make health-related claims related to GLP-1s in weight management contexts. There’s also a prohibition against trading or marketing high-risk goods and services, which theoretically covers the promotion of unauthorized pharmaceuticals. However, incoming modifications to community guidelines seem insufficient to regulate the spread of unapproved GLP-1 drugs, especially when external links are directed for purchasing purposes.

UltraViolet campaign director Jenna Sherman articulated the pressing nature of the issue, likening TikTok to "tech oligarchs" who prioritize profitability over user safety. This situation is exacerbated by the prevalence of sophisticated algorithms and the societal obsession with weight loss, which can create a potentially dangerous environment.

Broader Implications and Industry Response

The ramifications extend beyond TikTok itself. Pharmaceutical players are responding to the competitive landscape surrounding GLP-1 drugs with notable legal actions. Last week, Novo Nordisk, the producer of Wegovy and Ozempic, filed a lawsuit against Eli Lilly, another pharmaceutical company behind products like Zepbound and Mounjaro, citing deceptive marketing practices. In 2025, both companies collectively invested around $700 million in advertising their drugs.

Social media users, particularly those recovering from eating disorders, have expressed feeling overwhelmed by the volume of GLP-1 advertisements infiltrating their feeds. Reports indicate that attempts to block or filter this content often fall short, underscoring the pressing need for more accountable advertising practices on social media platforms.

As the pressure mounts, the crucial question remains: Will TikTok take effective measures to address the gray market for GLP-1 drugs, ensure user safety, and align its community guidelines with public health imperatives? With no official response from TikTok regarding UltraViolet's findings at the time of publication, the situation warrants close observation.

The information contained in this article is not intended as health or medical advice. Always consult a qualified professional with questions about a medical or health issue.